DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Saturday, 30 January 2016

Jennifer Riggs-Sauthier, Ph.D. Vice-President, Chemistry at Nektar Therapeutics

Jennifer Riggs-Sauthier, Ph.D..


Jennifer Riggs-Sauthier, Ph.D.

Vice-President, Chemistry at Nektar Therapeutics
  

Nektar Therapeutics
  • Research And Development
    San Francisco, United States



Highly skilled leader with 16 yr experience in drug discovery & development within the pharmaceutical industry. Committed to focused drug discovery with an emphasis on structure-guided drug design & critical thinking. Results driven leader with a proven record of achievement & success. Provide oversight & guidance to multidisciplinary research teams to build the pipeline & deliver high quality drug candidates to the clinic in support of company objectives. Emotional intelligence practitioner. 

 

links

 https://www.linkedin.com/in/jenniferariggs
 https://www.facebook.com/jennifer.riggssauthier
 drjariggs14@me.com
 https://twitter.com/drjriggs @drjriggs
 https://www.researchgate.net/profile/Jennifer_Riggs-Sauthier/info
 https://communities.acs.org/docs/DOC-12035
 http://liveinstagram.com/UserMedia/1283971144
 Jennifer A. Riggs-Sauthier

Lives in San Francisco, California
301 King Street 1700, San Francisco, California, 94158 Phone: (256) 527-9605 
Lived in Raleigh, North Carolina · Lived in South Bend, Indiana

 

Summary

Strategic, accomplished leader with 17 years experience in drug discovery and development within the pharmaceutical industry. Extensive leadership experience in positions of increasing responsibility across a global organization. Committed to focused drug discovery with an emphasis on structure-guided drug design and critical thinking. Builder of highly productive teams and results driven leader with a proven record of achievement and success. Provide oversight and guidance to multidisciplinary research teams across a global organization to grow the pipeline and deliver high quality drug development candidates to the clinic in support of broad company objectives while also managing external relationships with CROs. Effectively lead cross-functionally in a matrix environment while exerting personal influence. Maintain a steady flow of novel small molecule and biologics candidates across various therapeutic areas to support the pipeline. Contribute to company intellectual property and grow the patent portfolio. Skillful with scientific presentations to potential investors, Investor Relations R&D Day, and business partners. Efficient management of research budget with corporate finance. Experienced in organizing Research Symposia and Advisory Boards. Dedicated mentor.

Specialties: Scientific Leadership & Management; Emotional Intelligence; Organic & Medicinal Chemistry; Structure-guided drug design; Drug Discovery & Development; Small Molecule & Biologics Drug Conjugates; Employee development; Project leadership; Global CRO Management; Excellent problem solving skills.

Software Skills: Outlook, Powerpoint, Word, Excel, Project, OneNote; Pages, Numbers, Keynote; MindManager, Evernote, EndNote, SharePoint, ChemBioDraw, Chem 3D, E-Notebook,Compound Registration

Follow what I am reading:
http://www.shelfari.com/jariggs/shelf
http://www.goodreads.com/user/show/11156365-jennifer

 

 

 

Methods of treating inflammatory conditions of the gastrointestinal tract using 4-APAA and compositions thereof
US 6903082 B2

US6903082 

Nobex Corporation

 

 

 

Experience





Vice-President, Chemistry

Nektar Therapeutics
– PresentSan Francisco Bay Area
Roles:
- Member of the Senior Leadership Team, Research Executive Team and Head of Chemistry
- Routinely communicate to Executive Management the status of highly visible research programs
- Develop Nektar platform and pipeline with novel drug development candidates
- Support discovery, pre-clinical, and IND-enabling activities leading to 1-2 development candidates/yr
- Reviewer of non-clinical sections for both IND and NDA submissions
- Member of the Nektar / Astra Zeneca Movantik™ (Naloxegol) team from Discovery to Launch
- Maintain and develop Nektar’s research patent portfolio with legal department
- Thoughtful selection of targets and diseases, define target product profiles
- Identify, support, and evaluate external business collaboration opportunities
- Deliver key scientific presentations to potential investors and business partners.
- Responsible for execution of annual Research Symposium & Advisory Boards
- Efficient management of research budget with corporate finance to a total ~$50 million

Leadership Training:
- Leading for Organizational Impact, CCL
- Becoming a Conflict Competent Leader
- Developing Emotional Intelligence, Talent Smart

Achievements:
- Skillful & accomplished in building a lean, highly motivated & productive, efficient,creative, unified and successful chemistry team.
- Dynamic leadership that focuses on a sense of urgency, accountability, project cycle times, employee buy-in, and scientific excellence. Experience complementing internal research infrastructure with outsourcing to CROs.
- Built a robust pipeline of novel drug candidates across a number of therapeutic areas (Immunotherapy, Rare Diseases, Oncology, Pain)
- Successfully lead global project teams ~ 20 scientists to rapidly deliver critical results
- Global implementation of a E-Notebook & Chemical Informatics system to increase efficiency & transparency.
- Presentations (30+); peer reviewed publications (30); co-inventor 40+ patents




Senior Director, Science & Technology, Small Molecule Pharmaceuticals

Nektar Therapeutics
– (2 years 6 months)Huntsville, Alabama Area
• Successful leadership of the small molecule medicinal chemistry group resulting in a highly productive and efficient team of 10 scientists with $5.0 million budget.
• Build and maintain a pipeline of novel small molecule candidates across a number of therapeutic areas (Oncology, Pain, Antiviral, Antihistamine, and Infectious Disease).
• Actively contribute and encourage inter-disciplinary communication as a core team member on 9 small molecule pre-clinical and development programs.
• Successfully lead project teams of up to 12 scientists through matrix management across 3 sites to rapidly deliver critical results.
• Liase with stakeholders in other discovery departments to evaluate biological rationale / available assets regarding new targets.
• Design and construct in collaboration with IT a global SharePoint site for all of Research to enhance inter- and intra-departmental communication and promote transparency.
• Initiate the employment of in silico modeling to support structure-guided drug design and successfully collaborated / managed a computational / molecular modeling consultant for results.
• Manage with high productivity several Contract Research Organizations (CROs) both foreign and domestic to support and supplement internal resources.
• Implementation in collaboration with EH&S a controlled substance program and license for research at Huntsville, AL site to include Schedules II-V.
• Represent Nektar’s science to partners, investors, Advisory and KOL boards, consultants, and the scientific community.




Director, Science & Technology, Small Molecule Pharmaceuticals

Nektar Therapeutics
– (1 year 1 month)Huntsville, Alabama Area
Directed activity of 10 scientists in the small molecule group which is responsible not only for all medicinal chemistry aspects of applying the Nektar PEGylation technology to drug molecules from rational design through screening but also is a major source of ideas, concepts, and new IP generation for the Company’s pharmaceutical development. Successfully managed a number of CROs to support medicinal chemistry efforts. Additional responsibilities included leading and participating on teams at three sites including Hyderabad, India; San Carlos, CA and Huntsville, AL. Integral in the transferring of programs from Discovery/Research Phase to Development. Managed up to $2.0 million budget.




Associate Director, Science & Technology, Small Molecule Pharmaceuticals

Nektar Therapeutics
– (3 years 1 month)Huntsville, Alabama Area
Directed activity of 10 scientists in the small molecule group which is responsible not only for all medicinal chemistry aspects of applying the Nektar PEGylation technology to drug molecules from rational design through screening but also is a major source of ideas, concepts, and new IP generation for the Company’s pharmaceutical development. Successfully managed a number of CROs to support medicinal chemistry efforts. Additional responsibilities included leading and participating on teams at three sites including Hyderabad, India; San Carlos, CA and Huntsville, AL. Integral in the transferring of programs from Discovery/Research Phase to Development. Managed up to $2.0 million budget.




Group Leader, Drug Discovery & Chemical Innovation Group

Nobex Corporation
– (5 years 4 months)Raleigh-Durham, North Carolina Area
• Successful leadership of the Drug Discovery & Chemical Innovation Group: Synthetic Organic Research Scientists – 3 Ph.D., 3 M.S./B.S. level synthetic chemists; Analytical Research Scientists – 1 Ph.D, 2 M.S./B.S. level analytical chemists.
• Directed and managed medicinal / synthetic chemistry activities (derivatization of proteins, peptides, and small molecules with assessment of bioactivity through in vitro, in vivo, and oral bioavailabilty screening) on up to 10 projects according to company project priorities
• Interacted and promoted scientific discussions with cell pharmacology, animal pharmacology, analytical chemistry, clinical & regulatory, chemical development & manufacturing, formulation, and computational chemistry
• Project team lead on 5 different successful cross-functional project teams; 3 of which were partnered with Top 5 Pharmaceutical Companies (GSK, Pfizer, and BMS) in the areas of diabetes, metabolic disease, and obesity.
• Facilitated team meetings, mediated issue resolution, assigned action items, drove projects to completion over aggressive timelines
• Reviewer, primary synthetic chemist and member of IND filing team for APAZATM (small molecule for IBD)
• Participated in due diligence sessions with outside companies for product out-licensing
• Created and worked with CRO to generate Nobex Oligomer Library – 500 compounds that were prepared by automated & parallel syntheses techniques
• Scientific liaison and consultant with Business Development for Technology Application Deals
• Identification and evaluation of New Technologies or Drug Discovery Opportunities for in-licensing or creative partnerships
• Participated in intellectual property brainstorming sessions
• Prepared and reviewed patent applications in collaboration with in-house counsel
• Represented Nobex’s science to partners, investors, consultants, and the scientific community
• Served as Chemical Hygiene Officer on safety team




Postdoctoral Research Associate

North Carolina State University
– (1 year 11 months)Raleigh-Durham, North Carolina Area
Research under the direction of Dr. Jonathan S. Lindsey (Glaxo Distinguished University Professor of Chemistry) included: 1) Investigation of conditions in porphyrin-forming reactions using an automated chemistry workstation and 2) Synthesis and development of novel porphyrin systems vital to the understanding of electronic communication in the design of efficient molecular photonic devices.




Research Chemist

Shearwater Polymers
– (8 months)Huntsville, Alabama Area
A chemical company involved with the development and manufacture of functionalized biocompatible poly(ethylene glycol) for academic, pharmaceutical, and biotechnical applications. Responsibilities included: Syntheses and development of poly(ethylene glycol) derivatives, execution of GMP procedures for large scale polymer production, and organization of chemical laboratory at company's inception.

 

Education




University of California, Berkeley, Haas School of Business

Certificate of Business Excellence

Financial Analysis for Non-Financial Executives (FANFE) - Certificate (May 2013)
Corporate Business Model Innovation (CBMI) - Certificate (October 2013)
The Innovative Organization - Certificate (October 2014)
Strategy in Competitive Markets - Certificate (May 2015)
Negotiations and Influence - Certificate (June 2015)



University of Notre Dame

Doctor of Philosophy (Ph.D.), Organic Chemistry

Research under the direction of Dr. Bradley D. Smith included: Property-directed organic synthesis of novel, complex small molecule systems containing boronic acid, quaternary ammonium cation, and ruthenium (III) metallocene moieties for the molecular recognition of saccharides and nucleoside phosphates with further application in membrane separations and transport.

Graduate Student Mentor for undergraduate chemistry majors 1994-1997
Teaching Assistant 1993-1996
Student Leader of Organic Literature Meetings, University of Notre Dame, 1996 - 1997



University of Alabama in Huntsville

Bachelor’s Degree, Chemistry

Undergraduate Research Assistant - 1992

Research under the supervision of Dr. Richard S. Lumpkin involved the syntheses and characterization of polypyridine-transition metal complexes for use as chromophore sensitizers.

Undergraduate Research Assistant - 1992

Research under the supervision of Dr. Thomas M. Leslie involved the synthesis and characterization of various polyurethanes for use in non linear optical devices.

Undergraduate Research Assistant - 1990-1992

Research under the supervision of Drs. James M. Van Alstine and J. Milton Harris involved electrokinetic measurements involving various polymer coatings on glass as well as polystyrene latex bead surfaces and their ability to prevent protein adsorption on those surfaces thus providing critical control of electroosmosis.

Teaching Assistant 1990-1992
Resident Assistant 1990-1991
Chemistry Stockroom Assistant 1990

 
•National Association of Professional Women (NAPW) Woman of the Year, 2013-2014
•Who’s Who in Science and Engineering, 1998-1999
•Reilly Fellowship, University of Notre Dame, 1997 - 1998
•J. Peter Grace Fellowship, University of Notre Dame, 1996 - 1997
•NASA Undergraduate Fellowship, University of Alabama in Huntsville, 1991 - 1992
•Highest Undergraduate Achievement in the Department of Chemistry, 1992
•Who's Who on National Dean's List, 1988 - 1992
•Honor Scholar, 1988 - 1992
•Granted Scholarship Renewal, 1989 - 1992
•American Institute of Chemist Award, 1991
•Who's Who in American Colleges and Universities, 1990 - 1991
•National Collegiate Natural Sciences Award, 1990 - 1991
•Academic All-American, 1990 - 1991
•Outstanding High School Senior Scholarship, 1988 - 1989
• Member, Omicron Delta Kappa - Leadership Honor Society, 1990 - present
Vice-President, 1991 - 1992
• Member, Alpha Lambda Delta - Freshman Honor Society, 1988 - 1992
Secretary, 1989 - 1990

 Big_thumb_25f20c73-e87d-ea10-4fd1aee8e3841728
 Patents


·      6-Methoxy-2-Naphthylacetic Acid Prodrugs, Ekwuribe, N. N.; Riggs-Sauthier, J. A.
o    US Patent 6,436,990 (Aug. 20, 2002);
o    US Patent 6,552, 078 (Apr. 22, 2003);
o    US Patent 6,610,739 (Aug. 26, 2003);
o    US Patent 6,653,348 (Nov. 25, 2003);
o    US Patent 6,713,510 (Mar. 30, 2004);
o    US Patent 6,730,701 (May 4, 2004)



·     5-ASA Derivatives Having Anti-Inflammatory and Antibiotic Activity and Methods of
    Treating Diseases Therewith, Ekwuribe, N. N.; Riggs-Sauthier, J.A.
US Patent 6,458,776 (Oct. 1, 2002)

·      Immunoregulatory compounds and Derivatives and Methods of Treating Diseases Therewith,
    Ekwuribe, N. N.; Riggs-Sauthier, J.A.
    US Patent 6,583,128 (Jun. 24, 2003)
    US Patent 7,119,119 (Oct. 10, 2006)
    US Patent 7,151,095 (Dec. 19, 2006)

·      Methods of Treating Inflammatory Conditions of the Gastrointestinal Tract Using 4-APAA and
     Compositions Thereof, Ekwuribe, N.N.; Riggs-Sauthier, J. A.
US Patent 6,903,082 (Jun. 7, 2005)



Membrane Process for Separating Carbohydrates. Smith, B. D.; Riggs, J. A.
US Patent 5,800,624 (Sep. 1, 1998)

PUBS



1.     A Role for Novel, Orally Available Mu-Opioid Agonists with Both Centrally and Peripherally Mediated Analgesia in the Treatment of Neuropathic Pain. Webster, L.; Gursahani, H.; Ali, C.; Choi, I.; Riggs, J.; Gogas, K.; Iverson, M.; Medve, R.; Odinecs, A.; Eldon, M.; Evans, J.; Quach, P.; Trinchero, P.; Hennessey, M.; Harrison, S.  4th International Congress on Neuropathic Pain. June 2013.
  1. Absorption of Polyethylene Glycol (PEG) Polymers: The Effect of PEG Size on Permeability. Gursahani, H.; Riggs-Sauthier, J.; Pfeiffer, J.; Lechuga-Ballesteros, D.; Fishburn, S. J. Pharm. Sci. 2008.

  1. The Benefits and Challenges of PEGylating Small Molecules. Riley, T.; Riggs-Sauthier, J. Pharmaceutical Technology 2008.

  1. Combinatorial Synthesis of PEG Oligomer Libraries. Wang, H.-J.; Dolan, J.; Chen, Z.; Gregg, B.; Riggs-Sauthier, J. Org. Process Res. Dev, Manuscript submitted.

  1. Synthesis and Efficacy of Novel 5-Aminosalicylic Acid (5-ASA) – Containing Pro-drugs For the Treatment of Inflammatory Bowel Disease. Bioorg. Med. Lett., in preparation.

  1. Synthesis and Anti-Inflammatory Efficacy of a Series of Novel 6-Naphthylacetic Acid (6-MNA) Prodrugs. J. Med. Chem, in preparation.

  1. Convenient Synthesis of a Water-Soluble, Discrete PEG Paclitaxel Prodrugs. Karg, M.; Riggs-Sauthier, J.; Dugdell, R.; Odenbaugh, A.  Bioconjugate Chem. Manuscript submitted.

  1. Inhibition of Clostridium difficile Toxin A-Induced Colitis in Rats by APAZAÔ.  McVey, D.; Liddle, R.; Riggs-Sauthier, J.; Ekwuribe, N.; Vigna, S. Dig. Dis. Sci. 2005, 50, 565-573.

  1. "Automated chemistry workstation operations guide and help manual. Version 2," Dixon, J. M.;  Wagner, R. W.; Du, H.; Li, F.; Riggs-Sauthier, J. A.; Lindsey, J. S. North Carolina State University,  Department of Chemistry, 2004, Technical Report TR04-1.

  1. Investigation of Acid Cocatalysis in Syntheses of Tetraphenylporphyrin. Geier, G. R., III; Riggs, J. A.; Lindsey, J. S. J. Porphyrins Phthalocyanines 2001, 5, 681-690.

  1. Design and Synthesis of Porphyrin-Based Optoelectronic Gates.  Ambroise, A.;  Wagner, R.;  Rao, P.; Riggs, J.A.;  Hascoat, P.;  Diers, J.;  Seth, J.;  Lammi, R.;  Bocian, D.;  Holten, D.;  Lindsey, J.S.  Chem. Mater. 2001, 13(3), 1023-1034.

  1. Excited-State Energy Transfer and Ground-State Hole/Electron Hopping in p-Phenylene-Linked Porphyrin Dimers.  Yang, S.;  Seth, J.;  Riggs, J.A.;  Arai, T.;  Kim, D.;  Bocian, D.;  Holten, D.;  Lindsey, J.S.  J. Phys. Chem. B 1998, 102, 9426-9436.
  2. Facilitated Transport of Carbohydrates, Catecholamines, and Amino Acids Through Liquid and Plasticized Organic Membranes.  Smith, B.D.;  Gardiner, S.J.;  Munro, T.A.;  Paugam, M.-F.;  Riggs, J.A. J. Mol. Rec. Incl. Phenom. 1998, 32, 121-131.

  1. Facilitated Transport of Small Carbohydrates through Highly Stable Plasticized Cellulose Triacetate Membranes.  Evidence for Fixed-Site Jumping Transport Mechanism.  Riggs, J.A.;  Smith, B.D. J. Am. Chem. Soc. 1997, 119, 2765-2766.

 MORE.............

  1. Munro, T.A.; Riggs, J.A.;  Smith, B.D.  Macrocyclic Host Molecules. In Macmillan Encyclopedia of Chemistry; Lagowski, J.J., Ed.;  Volume 2;  Macmillan Reference USA, Simon & Schuster Macmillan:  New York, 1997; pp  427-431.

  1. High Fructose Syrup Production using Fructose-Selective Liquid Membranes.  Paugam, M.-F.;  Riggs, J.A.;  Smith, B.D., Chem. Commun. 1996, 22, 2539-2540.

  1. Nucleotide Carrier Mixture with Transport Selectivity for Ribonucleoside-5'-phosphates. Riggs, J.A.;  Hossler, K. A.;  Smith, B.D.;  Karpa, M.J.;  Griffen, G.;  Duggan, P.J., Tetrahedron Lett. 1996, 37, 6303-6306.

  1. Molecular Recognition and Membrane Transport with Mixed-Ligand Borates.  Riggs, J.A.; Litchfield, R.K.;  Smith, B.D., J. Org. Chem. 1996, 61, 1148-1150.

  1. Protein-Rejecting Ability of Surface-Bound Dextran in End-On and Side-On Configurations – Comparison to PEG.  Österberg, E.;  Bergström, K.;  Holmberg, K.;  Schuman, T.;  Riggs, J.A.; Burns, N.;  Van Alstine, J.M.;  Harris, J.M.  J. Biomed. Mater. Res.  1995, 29, 741-747.

  1. Electrokinetic Characterization of Hydrophilic Polymer Coatings of Biotechnical Significance.  Van Alstine, James M.;  Burns, Norman L.;  Riggs, Jennifer A.;  Holmberg, Krister;  Harris, J. Milton, Colloids and Surfaces 1993, 77, 149-158.

  1. Comparison of Polysaccharide and Poly(ethylene glycol) Coatings for Reduction of Protein Adsorption on Polystyrene Surfaces.  Österberg, Eva;  Bergström, Karin;  Holmberg, Krister;  Riggs, Jennifer A.;  Van Alstine, James M.;  Schuman, Thomas P.;  Burns, Norman L.;  Harris, J. Milton, Colloids and Surfaces 1993, 77, 159-169.


 PRESENTATIONS



1.     The Discovery of a Multi-Arm Polymer Conjugated Taxane with Improved Efficacy in a Tumor Xenograft Model (poster). Ren, Z.; Zhang, W.; Kozlowski, A.; Fry, D.; Hoch, U.; Brew, C.; Lee, S.; Dahhani, F.; Riley, T.; Harrison, S.; Riggs, J. 246th American Chemical Society National Meeting, Indianapolis, IN, September 8-12, 2013.

2.     Development of A Novel Intravenous Calcimimetic for End Stage Renal Disease (ESRD) Patients on Dialysis (poster). Dixit, V.; Cheng, L.; Zhang, J.; Jaladi, R.; Tonkin, L.; Obalapur, P.; Dodda, S.; Shrivastava, W.; Dama, S.; Kesana, S.; Rubas, W.; Fry, D.; Martin, D.; Riggs, J.; Kantak, S.; Harrison, S.; Doberstein, S. 50th ERA-EDTA Kidney Congress, Istanbul, Turkey, May 18-21, 2013.

3.     Polymer-Conjugated Taxane Shows Improved Efficacy in Tumor Xenograft Models (poster). Fry, D.; Brew, C.; Hoch, U.; Zhang, W.; Lee, S.; Harrison, S.; Riggs, J. AACR Annual Meeting, Washington DC, April 6-10, 2013.

4.     Novel Thymidylate Synthase Inhibitor NKT-TSI-4a Shows Improved PK Profile and Superior Efficacy Compared to Pemetrexed (poster). Brew, C.; Lee, S.; Jaladi, R.; Cheng, L.; Dama, S.; Riggs-Sauthier, J.; Fry, D.; Harrison, S. EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, Dublin, Ireland, November 6-9, 2012.

5.     NKTR-171:  A Novel Sodium Channel Blocker for Neuropathic Pain with Reduced CNS Side Effects (poster). Gursahani, H.; Choi. I.; Deng, B-L.; Dodda, S.; Evans, J.; Grace, K.; Guillon, M.; Harrison, S.; Mangadu, B.; Pfeiffer, J.; Riggs-Sauthier, J.; Riley. T.   42nd Annual Meeting, Society of Neuroscience, New Orleans, LA, October 13-17, 2012.      



MORE...............

1.     Preclinical Pharmacology of Mu Opioids-A Comparison of Morphine, Oxycodone, Hydrocodone, and Fentanyl in Rodent Pain Models (poster). Choi, I.; Ali, C.; Evans, J.; Gogas, K.; Guillon, M.; Gursahani, H.; Harrison, S.; Kim, G.; McWeeney, D.; Pfeiffer, J.; Quach, P.; Riggs-Sauthier, J.; Trinchero, P. Riley, T.  42nd Annual Meeting, Society of Neuroscience, New Orleans, LA, October 13-17, 2012.      

2.     NKTR-181: A Novel, Orally Available Mu Opioid Agonist with Reduced Rate and Extent of CNS Exposure Exhibits Comparable Analgesic Efficacy but Reduced Abuse Liability and CNS Side Effects Compared to Oxycodone (poster)  Gursahani, H; Gogas, K. Pfeiffer, J.; Choi, I.; Evans, J.; McWeeney, D.; Pfeiffer, J.; Ali, C.; Choi, I.; Quach, P.; Trinchero, P.; Gauvin, D.; Fishburn, S.; Harrison, S.; Doberstein, S.; Riley, T; Riggs-Sauthier, J. International Conference on Opioids, Boston, MA, June 10-12, 2012.

3.     Invited Speaker: Strategies for Improving the Performance of Small Molecule Therapeutics from Discovery to the Clinic:  A Case Study of NKTR-102, a Novel Topoisomerase I Inhibitor-Polymer Conjugate. Riggs-Sauthier, J.  9th International Symposium on Polymer Therapeutics (ISPT), Valencia, Spain, May 28-30, 2012.

4.     Invited Speaker: The Design of Novel and Improved Therapeutics Utilizing Nektar’s Advanced Polymer Conjugation Technology. Riggs-Sauthier, J.  World Molecular Engineering Network, Los Cabos, Mexico May 6-9, 2012.

5.     Invited Speaker: Improving the Performance of Small Molecule Therapeutics Using Nektar’s Advanced Polymer Conjugation Technology. Riggs-Sauthier, J.  University of Mississippi Department of Chemistry & Biochemistry Colloquium Series, Oxford, Missisippi April 19, 2012.

6.     Pharmacological characterization of an orally active opioid analgesic with rapid onset of activity and low abuse liability. (poster) Ali, C.;  Choi, I.; Evans, J.;  Fishburn, S.; Gogas, K.; Guillon, M.; Gursahani, H.; Harrison, S.; Kim, G.;  Lee, M.; Mangadu, B.; McWeeney, D.;  Pfeiffer, J.; Quach, P.; Riggs, J.;  Phillips, G.; Trinchero, P.; Wong, S.; Riley, T. 41st Annual Meeting, Society of Neuroscience, Washington DC, 2011.      

7.     Invited Speaker: Strategies for Improving the Performance of Small Molecule Therapeutics from Discovery to the Clinic:  A Case Study of NKTR-102, a Novel Topoisomerase I Inhibitor-Polymer Conjugate. Riggs-Sauthier, J.  Madison Marshall Symposium, North Alabama Section of the American Chemical Society Meeting, Huntsville, Alabama May 17, 2011.

8.     Invited Speaker: Improving the Bioavailability of Small Molecule Drugs Through the Use of Nektar’s Advanced Polymer Conjugation Technology. Riggs-Sauthier, J. 10th edition of the Medicinal Bioorganic Chemistry Foundation meeting, Steamboat, Colorado, 2011.

9.     Controlling the Rate of Entry to the CNS by Polymer Conjugation. (poster)  Gursahani, H.; Wong, S.; Riggs-Sauthier, J.; Pfeiffer, J.; Allums, S.; Zhang, W.; Deng, B-L.; Trinchero, P.; Quach, P.; Brew, C.; Evans, J-A.; Harrison, S.; Doberstein, S.; Riley, T.A.; Fishburn, C.S. 40th Annual Meeting, Society of Neuroscience, San Diego, CA, 2010.

10.   NKTR-181: A Novel Opioid Analgesic with Slowed CNS Entry Shows Reduced Abuse Liability and CNS Side Effects. (poster)  Fishburn, C.S.; Riggs-Sauthier, J.; Wong, S.; Pfeiffer, J.; Gursahani, H.; Muthukrishnan, E.; Ali, C.; Choi, I.; McWeeney, D.; Montague, L.; Harrison, S.; Doberstein, S.; Riley, T. 40th Annual Meeting, Society of Neuroscience, San Diego, CA, 2010.

11.   NKTR-105, a Novel PEGylated-Docetaxel, Demonstrates Superior Anti-tumor Activity Compared to Docetaxel in Human Non-Small Cell Lung and Colon Cancer Mouse Xenograft Models. (poster) Wolff, R.; Routt, S.; Hartsook, R.; Riggs, J.; Zhang, W.; Persson, H. Johnson, R.  20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, Geneva, Switzerland, 2008.

12.   Nektar R&D Day, Riggs-Sauthier, J. Intercontinental Hotel, New York City, New York, 2008.

 MORE..............

1.     Invited Speaker: Strategies for Improving the Performance of Small Molecule Therapeutics from Discovery to the Clinic:  A Case Study of NKTR-118, an Oral PEGylated Derivative of Naloxone. (poster) Riggs-Sauthier, J. 7th International Symposium on Polymer Therapeutics (ISPT), Valencia, Spain, 2008.

2.     Nektar R&D Day, Riggs-Sauthier, J. Palace Hotel, New York City, New York, 2007.

3.     Invited Speaker: Advanced PEGylation: Taking Biopharmaceuticals into the Future. Riggs-Sauthier, J. 33rd Annual Meeting and Exposition of the Controlled Release Society (CRS), Vienna, Austria, 2006.

4.     Invited Speaker: The Art of PEGylation: Advancing Peptide Drugs into the Future. Riggs-Sauthier, J. Natural Peptides to Drugs (NP2D) Conference, Zermatt, Switzerland, 2006.

5.     Invited Speaker:  Advanced PEGylation:  Taking Biopharmaceuticals into the Future.  Riggs-Sauthier, J. BIO 2005 Annual International Convention, Philadelphia, Pennsylvania, 2005.

6.     Strategies for Reversible Peptide PEGylation.  The TIDES Conference, Boston, Massachusetts, 2005.

7.     Invited Speaker: Strategies Toward the Oral Delivery of Insulin:  Using Molecular Modifications to Solve Drug Delivery Challenges.  Riggs-Sauthier, J.  ACS National Meeting, Anaheim, California, 2004.

8.     The Key to Oral Delivery of Proteins and Peptides:  Using Molecular Modifications to Solve Drug Delivery Problems. Riggs-Sauthier, J.  Drug Delivery Conference, Cherry Hill, New Jersey, 2003.

9.     Oral Delivery: Design of Carbamate Prodrugs and Structure- Activity Relationships. (poster) Dyakonov, T.; Riggs-Sauthier, J.; Harris, M.; Surguladze, D.; Bednarcik, M.; Ekwuribe, N. AAPS National Meeting, Toronto, Canada, 2002.

10.   Synthesis and Efficacy of Novel 5-Aminosalicylic Acid (5-ASA) – Containing Pro-drugs for the Treatment of Inflammatory Bowel Disease. (poster)  Riggs-Sauthier, J.A.; Malson, E.;  Harris, M.; Myung, S.;  Liddle, R.;  Ekwuribe, N.  ACS National Meeting, Boston, Massachusetts, 2002.

11.   Synthesis and Anti-Inflammatory Efficacy of a Series of Novel 6-Naphthylacetic Acid (6-MNA) Pro-drugs.  (poster)  Riggs, J.A.;  Dyakonov, T.;  Harris, M.;  Surguladze, Anderson, W.;  Myung, S.;  Jones, M.; Smalley, M.;  Ekwuribe, N.  ACS National Meeting, San Diego, California, 2001.

12.   Investigation of Conditions in Porphyrin-Forming Reactions Using an Automated Chemistry Workstation.  (poster)  Riggs, J.A.;  Wagner, R.W.;  Li, F.;  Du, H.;  Lindsey, J.S.,  ACS National Meeting, Anaheim, California, 1999.

13.   One-Flask Synthesis of 1,4-Phenylene-Linked Porhyrin Dimers and Their Rates of Energy Transfer. (poster)  Riggs, J.A.;  Arai, T.;  Lindsey, J.S.;  Holten, D.;  Bocian, D.F.,  ACS Southeastern Regional Meeting, Research Triangle Park, North Carolina, 1998.

14.   Innovative Liquid Membranes Launch High Fructose Syrup Production into the Next Generation. (poster)  Riggs, J.A.;  Smith, B.D.,  University of Notre Dame Poster Day, Notre Dame, IN, 1996.

15.   Molecular Recognition and Membrane Transport of Nucleoside Phosphates.  Riggs, J.A.; Hossler, K. A.; Smith, B.D.;  Karpa, M.J.;  Griffen, G.;  Duggan, P.J.,  ACS National Meeting, Orlando, Florida, 1996.

16.   Electrokinetic Detection of Biomedical Surface Phenomena.  (poster)  Riggs, J. A.;  Burns, N. L.;  Schuman, T.; Harris, J.M.;  Van Alstine, J.M., Alabama Materials Research Conference , Birmingham, Alabama, 1991 and ACS Southeastern Regional Meeting, Richmond, Virginia, 1991.

https://d.gr-assets.com/users/1342892478p8/11156365.jpg

San Francisco, California

 

 

 
 

///////
Posted by at No comments:
Labels: , , , , , ,
Subscribe to: Posts (Atom)